Pancreatic Perfusion Using Secretin and MRI

Sponsor
University of Nottingham (Other)
Overall Status
Unknown status
CT.gov ID
NCT02458118
Collaborator
(none)
15
1
1
48
0.3

Study Details

Study Description

Brief Summary

The purpose of this study is to assess pancreatic perfusion in patients with chronic pancreatitis at rest and after secretin stimulation and compare this to published data on pancreatic perfusion in normal subjects.

Condition or Disease Intervention/Treatment Phase
Phase 1/Phase 2

Detailed Description

Pancreatic blood flow or perfusion is difficult to quantify due to the complex vascular supply to the organ and its retroperitoneal location, adjacent to the abdominal aorta. The pancreas is supplied by the superior gastroduodenal artery from the celiac plexus, branches from the hepatic and splenic arteries, which originate from the celiac plexus, and the inferior gastroduodenal artery, which originates from the superior mesenteric artery. Identifying changes in flow in all these vessels with good spatial and temporal resolution is challenging but important in understanding many of the chronic conditions of the pancreas.

Chronic pancreatitis (CP) is an inflammatory condition of the pancreas leading to irreversible damage to the tissue. It is increasing in incidence in all nations, and is related to rising alcohol consumption and improved diagnostic techniques. In Europe the incidence is approximately 6-7/100,000 population. 73-91% of patients affected are male with an average age of 49-60yrs. Patients affected by CP have a high morbidity, such as diabetes and chronic abdominal and/or post-prandial pain in 80-90%, which required frequent hospital admission, control-drug prescriptions and intervention by specialist hospital services. However the mechanisms of chronic and post-prandial pain for CP patients are not well understood, but tissue ischaemia, inflammation and neurological changes have been proposed. These mechanisms may be inter-related with pancreatic inflammation and neurochemical changes, such as an increase substance P, which can produce vasoconstriction, reducing pancreatic perfusion and worsening ischaemia of intra-pancreatic nerves(3). A greater understanding of the ischaemic and inflammatory mechanisms behind the pain in CP, would greatly enhance the development of treatment for this and other debilitating conditions.

There are a few studies of pancreatic tissue perfusion in humans, those studies which have assessed perfusion have used invasive techniques such as endoscopic or laparoscopic measurement and hydrogen gas clearance methods. Although these methods have demonstrated decreased resting blood flow and little response to secretin stimulation in CP patients compared to healthy controls, the techniques are highly invasive, time consuming and expensive and can cause the participant significant morbidity. This has led to several non-invasive techniques including infusion of oxygen-15 water and positron emission tomography (PET), contrast-material-enhanced trans-abdominal ultrasound (US) or contrast-enhanced dynamic computer tomography (CT). However these techniques involve infusion of an exogenous marker to detect the change in flow rate and often require a radiation exposure or are operator dependant and give poor spatial or temporal resolution, limiting the usefulness of the studies.

MRI is an attractive alternative for the assessment of pancreatic perfusion, providing good spatial and temporal resolution with no radiation exposure. Two methods can be used, Contrast-Enhanced (CE) MRI or Arterial Spin Labelling (ASL) techniques. ASL provides a tool for quantitative assessment of tissue perfusion without the need for contrast administration.

Contrast-enhanced MRI using gadodiamide has been used to explore the changes in pancreatic perfusion with secretin stimulation. This study in 10 healthy volunteers demonstrated that at rest there was a higher blood flow within the body and the tail of the pancreas, compared to the head. With secretin stimulation there was a significant increased perfusion in all regions of the pancreas. ASL techniques, do not require exogenous contrast agents, only two previous studies have measured pancreatic perfusion with ASL, one exploring pancreatic exocrine functions in type 1 diabetics. A recent study at the Nottingham Digestive Diseases Centre on pancreatic perfusion measurement using ASL at baseline and after intravenous secretin stimulation has standardised the MRI technique of measuring pancreatic perfusion.

There are no studies using MRI ASL to measure pancreatic perfusion in patients with chronic pancreatitis after secretin stimulation. This pilot study aims to test the feasibility of using MRI ASL to measure pancreatic perfusion in patients with chronic pancreatitis with a view to perfecting the technique. This will allow future studies comparing pancreatic perfusion in healthy adult controls to patients with chronic pancreatitis thus improving the investigators understanding of the pathophysiology of pain in patients with chronic pancreatitis.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
15 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Study to Assess Pancreatic Blood Flow at Rest and During Stimulation Using Magnetic Resonance Imaging (fMRI) in Patients With Chronic Pancreatitis
Study Start Date :
Jun 1, 2012
Anticipated Primary Completion Date :
Apr 1, 2016
Anticipated Study Completion Date :
Jun 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: Secretin

Secretin 1 IU/kg over 3 min

Drug: Secretin
Secretin 1 IU/kg over 3 min
Other Names:
  • Secrelux" Sanochemia Pharmazeutika AG, Wein, Germany)
  • Outcome Measures

    Primary Outcome Measures

    1. Blood flow to pancreas as measured by arterial spin labelling MRI [1.5 hours]

    Secondary Outcome Measures

    1. Change in blood flow to pancreas after intravenous secretin [1.5 hours]

    2. Pancreatic diffusion [T 0, 5, 10, 20, 30, 40]

    3. Pancreatic volume [T 0, 5, 20, 40]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Adults with chronic pancreatitis (as defined by the Cambridge criteria)
    Exclusion Criteria:
    1. Allergy to secretin

    2. Claustraphobia

    3. Refusal to consent for the study

    4. MRI contraindications e.g. pacemaker, artificial heart valve

    5. Previous abdominal surgery except appendectomy or hernia repair

    6. History of chronic abdominal pain from causes other than pancreatitis eg. inflammatory bowel or coeliac disease

    7. Pregnant women (safety concerns from injection of secretin)

    8. Patients younger than 18 years of age

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 1.5T Brain and Body Imaging centre, University of Nottingham Campus Nottingham Nottinghamshire United Kingdom NG7 2RD

    Sponsors and Collaborators

    • University of Nottingham

    Investigators

    • Principal Investigator: John Simpson, University of Nottingham

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    University of Nottingham
    ClinicalTrials.gov Identifier:
    NCT02458118
    Other Study ID Numbers:
    • 11109
    First Posted:
    May 29, 2015
    Last Update Posted:
    Feb 18, 2016
    Last Verified:
    Feb 1, 2016
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by University of Nottingham
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 18, 2016